Faster Launch, Increased Adoption, Higher Revenue, and a Playbook for Commercial Success. Read the white paper.
Download Now
Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • Prognos Factor®
    • Marketplace
      • Explore & Buy Data
      • Become a Data Provider
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey Software
      • Physician Segmentation
      • Outcomes Insights
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
  • Company
    • Careers
    • News
    • Insights
    • Resources
  • Contact Us
Home Insights Comorbidity Between Diabetes and RA

Comorbidity Between Diabetes and RA

  • November 9, 2017
  • Posted in Disease Awareness

This post was last updated on December 2, 2019 at 9:42 pm

How is comorbidity affected by a double positive?

By Jason Bhan, MD, Fernando Schwartz, PhD, and Lauren Wiener>

If you read our previous blog, you know that Prognos has set out to prove that diabetes and rheumatoid arthritis are comorbid conditions.  In today’s blog we are ready to share our findings with our readers.

As a reminder, we hypothesized that our analysis would point to a comorbidity between diabetes and RA, and also set out to investigate whether patients with a double positive RA diagnosis would be affected by the presence of a diabetes comorbidity.  We searched the expansive Prognos Registry to find patients with diabetes and RA, as well as double positive RA patients (RF+ and anti-CCP+) and performed detailed analyses, including a chi square test, to find statistically significant differences between populations.

Study Results: Comorbidity

The Prognos Registry contains 24,252,264 patients with type 2 diabetes, and 2,114,010 patients with RA. Of these patients, 608,540 are comorbid and are diagnosed with both type 2 diabetes and RA. These results mean that 28.79% of RA patients have diabetes, which is a significant comorbidity, and is similar to the 31% reported in a research study with 340 RA patients. Our results also show that 2.51% of diabetes patients have RA, which is a striking comorbidity given that RA is absent from current standards of care guidelines for diabetes.

Screen Shot 2017-11-09 at 2.51.58 PM

The Prognos database currently has a total of over 175 million patients across all conditions. Of the patients in the database, 13.799% have diabetes and 1.203% have RA. If the two diseases were independent, 0.166% of patients in the database would have diabetes and RA. However, 0.346% of patients in the Prognos database were found to have both diabetes and RA. Our findings report a comorbidity between diabetes and RA with an unprecedented sample size.

Study Results: Double Positive Risk Factor

Of the 2,114,010 RA patients, 121,546 were found to have a double positive diagnosis, and 1,992,464 were found to not have a double positive diagnosis. The distribution of the double positive patients between the just RA and comorbid population are shown in the table below:

Screen Shot 2017-11-09 at 3.00.02 PM

We were surprised to find that a double positive diagnosis is more common in the population suffering solely from RA rather than the comorbid population. Both RA and diabetes are inflammatory diseases, so a double positive could be expected to be more common in a comorbid population.

Of the patients that had only RA, 5.977% had a double positive diagnosis, and 5.187% of comorbid patients had a double positive diagnosis. A chi-square test was performed, which resulted in a chi-square statistic of 499.165, a p value of 2.2e-16, and one degree of freedom. The null hypothesis for the chi-square test is that there is no difference between the two populations. This small p value means we can reject the null hypothesis. The RA-only and comorbid populations differ with respect to a double positive diagnosis with a high degree of certainty.

What’s to Come…

Next week we’ll wrap up with our thoughts on what this could all mean.  As always, we encourage you to follow along with us and to reach out to us at info@prognos.ai with questions or to request additional information.

Reading List

  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454807/
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810070/
  • http://ard.bmj.com/content/69/7/1292
  • http://onlinelibrary.wiley.com/doi/10.1002/art.11223/full
  • http://onlinelibrary.wiley.com/doi/10.1002/1529-0131(200001)43:1%3C155::AID-ANR20%3E3.0.CO;2-3/full
« Diabetes and Rheumatoid Arthritis: A Missing Link?
Diabetes and RA: Further Explanations for Comorbidity »

Categories

  • AI
  • Alerts
  • Clinical
  • Commercial Launch Excellence
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Marketplace
  • Omnichannel Marketing
  • Patient Journey
  • Physician Segmentation
  • Prog Spotlight
  • RWD
  • Technology
  • Underwriting

Archives

Latest Tweets

Prognos HealthFollow

Query billions of fully-integrated lab & health records on more than 325M de-identified patients to answer key healthcare questions in minutes on prognosFACTOR.

Prognos Health
prognosAIPrognos Health@prognosAI·
12 Apr

In our recent panel discussion “How to determine your next best action for every HCP engagement”, leaders from Novartis, GSK, and Takeda Oncology discussed their #RWD strategies to commercialize drug therapies. 3 important best practices were revealed. https://prognoshealth.com/blog/provider-engagement/?utm_source=twitter&utm_medium=social&utm_campaign=provider_engagement_blog

Reply on Twitter 1513876896056057856Retweet on Twitter 1513876896056057856Like on Twitter 1513876896056057856Twitter 1513876896056057856
prognosAIPrognos Health@prognosAI·
7 Apr

68% of #pharma leaders believe the way #lifescience companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help address them.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=rwd_paradigm_shift_blog

#RealWorldData

Reply on Twitter 1512114401360461827Retweet on Twitter 15121144013604618271Like on Twitter 1512114401360461827Twitter 1512114401360461827
prognosAIPrognos Health@prognosAI·
5 Apr

Therapy-related #RWD insights and learnings for a new brand launch can take 12-18 months. One leading #pharma company cut this time in half. Find out how.
https://prognoshealth.com/resource/rwd-analysis/?utm_source=twitter&utm_medium=social&utm_campaign=oncology_case_study

#Omnichannel #Oncology #Pharmaceutical #TherapyLaunch #RealWorldData

Reply on Twitter 1511355425660325897Retweet on Twitter 15113554256603258971Like on Twitter 15113554256603258971Twitter 1511355425660325897
prognosAIPrognos Health@prognosAI·
3 Mar

In a recent survey of #pharma leaders by Reuters, 68% of respondents believe the way #LifeSciences companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=real_world_data_in_pharma_paradigm_shift

Reply on Twitter 1499488030222168066Retweet on Twitter 14994880302221680661Like on Twitter 1499488030222168066Twitter 1499488030222168066
prognosAIPrognos Health@prognosAI·
1 Mar

Dr. Steven Zatz Joins Prognos Health Board of Directors

"Steve’s vision and leadership helped build WebMD into an iconic healthcare brand," says @sundeepbhan1.

https://prognoshealth.com/about-us/news/press-release/dr-steven-zatz-joins-prognos-health-board-of-directors/?utm_source=twitter&utm_medium=social&utm_campaign=dr_zatz_joins_board

Reply on Twitter 1498679196536737795Retweet on Twitter 14986791965367377951Like on Twitter 14986791965367377951Twitter 1498679196536737795
Load More...
  • Prognos Factor®
    • Prognos Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2022. All Rights Reserved.

Get Answers Faster

Watch your questions answered with unparalleled speed. De-identified record level patient data already integrated & easily linked to other sources. Prognos puts you in control.

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.